Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with
reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30–40% of patients) …
reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30–40% of patients) …
Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients
L Uthman, A Baartscheer, CA Schumacher… - Frontiers in …, 2018 - frontiersin.org
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are the first antidiabetic compounds that
effectively reduce heart failure hospitalization and cardiovascular death in type 2 diabetics …
effectively reduce heart failure hospitalization and cardiovascular death in type 2 diabetics …
Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program
Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk
of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular …
of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular …
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
Aims We previously reported that in the EMPA-REG OUTCOME® trial, empagliflozin added
to standard of care reduced the risk of 3-point major adverse cardiovascular events …
to standard of care reduced the risk of 3-point major adverse cardiovascular events …
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Background The EXAMINE trial showed non-inferiority of the DPP-4 inhibitor alogliptin to
placebo on major adverse cardiac event (MACE) rates in patients with type 2 diabetes and …
placebo on major adverse cardiac event (MACE) rates in patients with type 2 diabetes and …
ECG signal preprocessing and SVM classifier-based abnormality detection in remote healthcare applications
Medical expert systems are part of the portable and smart healthcare monitoring devices
used in day-to-day life. Arrhythmic beat classification is mainly used in electrocardiogram …
used in day-to-day life. Arrhythmic beat classification is mainly used in electrocardiogram …
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
D Fitchett, J Butler, P van de Borne… - European heart …, 2018 - academic.oup.com
Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF)
hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in …
hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in …
sST2 predicts outcome in chronic heart failure beyond NT− proBNP and high-sensitivity troponin T
Background: Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to
inflammation and fibrosis. Objectives: This study assessed the independent prognostic value …
inflammation and fibrosis. Objectives: This study assessed the independent prognostic value …
The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary
R Kirk, AI Dipchand, DN Rosenthal… - The Journal of Heart …, 2014 - jhltonline.org
The writing group was chosen from the membership of the International Society for Heart
and Lung Transplantation (ISHLT), the Association of European Pediatric and Congenital …
and Lung Transplantation (ISHLT), the Association of European Pediatric and Congenital …
SGLT2-inhibitors; more than just glycosuria and diuresis
Heart failure (HF) continues to be a serious public health challenge despite significant
advancements in therapeutics and is often complicated by multiple other comorbidities. Of …
advancements in therapeutics and is often complicated by multiple other comorbidities. Of …